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Background: Previous studies have demonstrated preoperative anemia to be a strong risk factor for
periprosthetic joint infection (PJI) in total joint arthroplasty (TJA). Allogeneic blood transfusion can be
associated with increased risk of PJI after primary and revision TJA. Tranexamic acid (TXA) is known to
reduce blood loss and the need for allogeneic blood transfusion after TJA. The hypothesis of this study is
that administration of intravenous TXA would result in a reduction in PJI after TJA.
Methods: An institutional database was utilized to identify 6340 patients undergoing primary TJA be-
tween January 1, 2013 and June 31, 2017 with a minimum of 1-year follow-up. Patients were divided into
2 groups based on whether they received intravenous TXA prior to TJA or not. Patients who developed PJI
were identified. All PJI patients met the 2018 International Consensus Meeting definition for PJI. A
multivariate regression analysis was performed to identify variables independently associated with PJI.
Results: Of the patients included, 3683 (58.1%) received TXA and 2657 (41.9%) did not. The overall
incidence of preoperative anemia was 16%, postoperative blood transfusion 1.8%, and PJI 2.4%. Bivariate
analysis showed that patients who received TXA were significantly at lower odds of infection. After
adjusting for all confounding variables, multivariate regression analysis showed that TXA is associated
with reduced PJI after primary TJA.
Conclusion: TXA can help reduce the rate of PJI after primary TJA. This protective effect is likely inter-
linked to reduction in blood loss, lower need for allogeneic blood transfusion, and issues related to
immunomodulation associated with blood transfusion.
© 2019 Elsevier Inc. All rights reserved.Periprosthetic joint infection (PJI) is a rare, yet a devastating,
complication of total joint arthroplasty (TJA). It occurs in 1%-2% of
TJA procedures [1e3] and is one of the most common reasons for
TJA revision [4e10].
By 2030, primary TJA has been projected to grow by 174% to
572,000 for primary total hip arthroplasty (THA) and by 673% to
3.48 million for primary total knee arthroplasty (TKA) [11]. Failuresclosed potential or pertinent
ent, either direct or indirect,
the biomedical field which
rest with this work. For full
j.arth.2019.10.029.
n Orthopaedic Institute, 125 Sof TJA because of complications such as infection, loosening, peri-
prosthetic fracture, and postoperative pain are indications for
revision surgery [12]. These revisions will become a tremendous
burden to the health systems, with a projected estimate cost of $13
billion in 2030 [12]. Given the increased demands for arthroplasty,
patients should be perioperatively optimized to minimize the
incidence of PJI, and other complications, following TJA.
Preoperative anemia and blood loss during primary TJA leading
to allogeneic blood transfusion have been identified as risk factors
for surgical site infection (SSI) and PJI in TJA [13e16]. This has led to
a growing increase in the use of antifibrinolytic drugs to reduce
blood loss and blood transfusion post TJA [17]. The results from
previous studies and extensive meta-analysis have established that






Age (y), mean ± SD (range) 64.72 ± 10.7 (12-98)
Race (%)
Caucasian 4753 (75)




BMI (kg/m2), mean ± SD (range) 29.8 ± 5.3 (14-58.3)









SD, standard deviation; BMI, body mass index; TKA, total knee arthroplasty; THA,
total hip arthroplasty; TXA, tranexamic acid.
H. Yazdi et al. / The Journal of Arthroplasty 35 (2020) 840e844 841blood loss and the need for allogeneic blood transfusion post-TJA
[17e19].
Although efficacy of TXA in reducing blood loss and the need for
allogeneic blood transfusion has been well established, the poten-
tial role of TXA in reducing PJI following TJA has not been eluci-
dated. This study was conceived to examine the hypothesis that
administration of intravenous (IV) TXA can lead to a reduction in PJI
after primary TJA.
Materials and Methods
Following Institutional Review Board approval, a prospectively
maintained, single-institution database was queried to identify
7725 patients undergoing primary TJA between January 1, 2013 and
June 31, 2017. All patients who had primary THA or TKA were
included. For patients who had multiple joints replacement, each
joint was considered as a separate case. Patients undergoing revi-
sion arthroplasty, primary arthroplasty in tumor cases, and those
with inadequate follow-up (1012) were excluded (Fig. 1).
Overall, 6340 cases were included in the study with minimum
1-year follow-up. Of these, 2927 (46.2%) were male. The mean age
was 64.72 ± 10.7 years (range 12-98) and the mean body mass
index (BMI) was 29.8 ± 5.3 kg/m2 (range 14-58.3) (Table 1). The
mean follow-up was 26.3 months (range 12-67.3).
The cohort was divided into 2 groups: patients who received IV
TXA prior to arthroplasty (3683 patients) and those who did not
receive TXA (2657 patients). Patients in the TXA group were all
administered a single dose of TXA (15 mg/kg) intravenously, 20-
30 minutes prior to incision or inflation of tourniquet. The anti-
biotic and postoperative care was the same for both patient groups.
The majority of patients (91.8%) in the study received aspirin (325
mg/d or 81 mg bid) for 4 weeks postoperatively. Using the WorldFig. 1. Flow diagram detailing patient inclusion, exclusion, and grouping. TJA, total
joint arthroplasty; TXA, tranexamic acid.Health Organization definition, preoperative anemiawas defined as
hemoglobin (Hgb) <13 g/dL in males and Hgb <12 g/dL in females.
Patient demographics, comorbidities, operative details, and peri-
operative variables were recorded and compared across the 2
cohorts.
Patients who developed PJI following primary TJA were identi-
fied using the 2018 International ConsensusMeeting definition [20]
and subsequently confirmed by manual chart review.
Statistical Analyses
The 2 groups (TXA vs no TXA) were compared on categorical
variables with Fisher’s exact tests and on continuous variables with
t-tests for independent groups or Mann-Whitney U for nonpara-
metric variants. Preliminary bivariate logistic regression analyses
were conducted to determine whether various preoperative and
patient variables were significantly related to PJI outcomes. Vari-
ables which were related to PJI in the bivariate analyses (P < .25 as
recommended by Hosmer and Lemeshow, 2000) were considered
for logistic regression model. All analyses were conducted with the
statistical packages SPSS (IBM Corp, 2013, version 23, Armonk, NY).
Results
Overall, 3683 patients (58.1%) received IV preoperative TXA. The
overall incidence of preoperative anemia was 16%, postoperative
blood transfusion was 1.8%, and PJI rate was 2.4%. Most of TJA sur-
geries were done under neuraxial anesthesia (91.7%) and nearly all
(96.6%) of total knee replacements were done under tourniquet.
The preliminary analyses showed that patients receiving TXA
were younger, more likely to be female, had a lower BMI and
comorbidities, and undergoing THA. This group was also more
likely to receive aspirin (for deep vein thrombosis [DVT] prophy-
laxis) and had less anemia (all P < .05; Table 2). The outcome
measurement showed that the TXA group has a smaller post-
operative Hgb decrease, less need for allogeneic blood transfusion,
shorter length of hospitalization, less wound complications, and
lower PJI rate (all P < .05; Table 3). Intraoperative blood loss, 90-day
readmission, and postoperative thromboembolic events were
similar in both groups.
With regard to PJI rate, bivariate analyses (Table 4) showed that
rheumatoid arthritis (odd ratio [OR] 5.07, 95% confidence interval
Table 2
Univariate Analysis.
Variables Total (n ¼ 6340) Non-TXA (n ¼ 2657) TXA (n ¼ 3683) P-Value
Age (y), mean ± SD 64.7 ± 10.7 66.9 ± 10.5 63.1 ± 10.5 <.001
Gender, female (%) 3413 (53.8) 1306 (49.2) 2107 (57.2) <.001
BMI (kg/m2), mean ± SD 29.8 ± 5.3 30.0 ± 5.3 29.7 ± 5.3 .012
Race, Caucasian (%) 4753 (75.0) 1912 (72.0) 2841 (77.1%) <.001
Joint, knee (%) 3028 (47.8) 1369 (51.5) 1659 (45.0) <.001
CCI, mean ± SD 0.5 ± 1.0 0.8 ± 1.2 0.4 ± 0.8 <.001
CCI  1 (%) 2034 (32.1) 1111 (41.8) 923 (25.1) <.001
Diabetes (%) 379 (6.0) 190 (7.2) 189 (5.1) <.001
Malignancy (%) 68 (1.1) 37 (1.4) 31 (0.8) .036
Renal disease (%) 188 (3.0) 140 (5.3) 48 (1.3) <.001
Liver disease (%) 49 (0.8) 24 (0.9) 25 (0.7) .314
Rheumatic arthritis (%) 284 (4.5) 140 (5.3) 144 (3.9) .01
Preoperative hemoglobin (g/L), mean ± SD 13.3 ± 1.6 13.1 ± 1.8 13.5 ± 1.5 <.001
Anemia (%) 971 (16.0) 510 (20.9) 461 (12.7) <.001
Coagulopathy (%) 106 (1.7) 81 (3.1) 25 (0.7) <.001
Simultaneous bilateral TJA (%) 336 (5.3) 80 (3.0) 256 (7.0) <.001
Neuraxial anesthesia (%) 5812 (91.7) 2365 (89.2) 3447 (93.6) <.001
Tourniquet (%) 2925 (96.6) 1322 (96.6) 1603 (96.6) .93
Anticoagulation <.001
Aspirin (%) 5813 (91.8) 2304 (87.0) 3509 (95.3)
Warfarin (%) 330 (5.2) 255 (9.6) 75 (2.0)
Others 188 (3.0) 89 (3.4) 99 (2.7)
Intraoperative antibiotics .601
Cephalosporin (%) 5224 (82.5) 2182 (82.5) 3042 (82.6)
Vancomycin (%) 1082 (17.1) 452 (17.1) 630 (17.1)
Others (%) 23 (0.4) 12 (0.5) 11 (0.3)
Operative time (min), mean ± SD 101.5 ± 39.8 102.5 ± 40.5 100.9 ± 39.3 .111
TXA, tranexamic acid; SD, standard deviation; BMI, body mass index; CCI, Charlson comorbidity index; TJA, total joint arthroplasty.
Table 4
Bivariate Predictors of PJI via Logistic Regression.
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.000), higher Charlson Comorbidity Index (OR 1.27, 95% CI 1.13-1.43,
P ¼ .000), male gender (OR 1.58, 95% CI 1.14-2.20, P ¼ .005), renal
disease (OR 3.86, 95% CI 2.22-6.73, P ¼ .000), liver disease (OR 3.74,
95% CI 1.33-10.54, P ¼ .01), coagulopathies (OR 2.54, 95% CI 1.09-
5.88, P ¼ .03), longer length of hospital stay (OR 1.18, 95% CI 1.13-
1.23, P ¼ .000), longer operation time (OR 1.01, 95% CI 1.01-1.02, P ¼
.000), and anemia (OR 4.63, 95% CI 3.31-6.46, P ¼ .000) were
associated with higher odds of PJI. Administration of TXA (OR 0.47,
95% CI 0.34-0.66, P ¼ .000), neuraxial anesthesia (OR 0.32, 95%CI
0.21-0.48, P ¼ .000), and simultaneous bilateral surgeries (OR 0.24,
95% CI 0.06-0.96, P ¼ .04) were associated with lower odds of
infection.
After controlling for confounding variables, multivariate anal-







IOBL (mL), mean ± SD 147.8 ± 240.3 147.7 ± 159.5 .99
Hemoglobin drop (g/L),
mean ± SD
2.3 ± 1.8 2.0 ± 1.6 .000
Postoperative blood
transfusion (%)
75 (2.8) 41 (1.1) .000
Length of stay (d),
mean ± SD
2.4 ± 2.5 1.8 ± 1.4 .000
Wound complication (%) 35 (1.5) 15 (0.4) .000
DVT (%) 0 (0.0) 4 (0.1) .16
PE (%) 5 (0.2) 2 (0.1) .120
PJI (%) 90 (3.4) 60 (1.6) .000
Type of PJI (%) .68
Acute 27 (30.0) 16 (26.7)
Chronic 62 (68.9) 42 (70.0)
Hematogenous 1 (1.1) 2 (3.3)
90-d readmission (%) 120 (4.5) 155 (4.2) .55
TXA, tranexamic acid; IOBL, intraoperative blood loss; SD, standard deviation; DVT,
deep vein thrombosis; PE, pulmonary embolism; PJI, periprosthetic joint infection.P ¼ .04) was associated with lower rate of PJI. TXA also was more
effective in nonanemic patients (OR 0.52, 95% CI 0.32-0.84, P ¼
.008) and patients undergoing hip arthroplasty (OR 0.50, 95% CI
0.31-0.81, P ¼ .005) than anemic patients and those undergoing
knee arthroplasty (Table 5).Discussion
The association between preoperative anemia and SSI or PJI has
been demonstrated in numerous prior studies [13e16,21e24]. Pa-
tients with preoperative anemia have higher likelihood of needingPredictor OR (95% CI) P-Value
TXA 0.47 (0.34-0.66) .000
Age (y) 1.00 (0.99-1.02) .95
Male 1.58 (1.14-2.20) .005
BMI (kg/m2) 1.06 (1.03-1.09) .000
Race, not Caucasians 0.71 (0.47-1.07) .10
Knee 0.77 (0.55-1.06) .11
CCI scores 1.27 (1.13-1.43) .000
Diabetes 1.00 (0.51-1.99) .99
Malignancy 1.25 (0.30-5.17) .75
Renal disease 3.86 (2.22-6.73) .000
Liver disease 3.74 (1.33-10.54) .01
Rheumatic arthritis 5.07 (3.28-7.83) .000
Anemia 4.63 (3.31-6.46) .000
Coagulopathy 2.54 (1.09-5.88) .03
Simultaneous bilateral TJA 0.24 (0.06-0.96) .04
Neuraxial anesthesia 0.32 (0.21-0.48) .000
Warfarin 2.20 (1.54-3.15) .000
Vancomycin 2.20 (1.54-3.15) .000
Operative time (min) 1.01 (1.01-1.02) .000
Length of stay (d) 1.18 (1.13-1.23) .000
PJI, periprosthetic joint infection; OR, odds ratio; CI, confidence interval; TXA, tra-
nexamic acid; BMI, body mass index; CCI, Charlson comorbidity index; TJA, total
joint arthroplasty.
Table 5
Multivariate Analysis for Association Between TXA and PJI.
Variables PJI Rate Nonadjusted OR (95% CI) P-Value Adjust OR (95% CI) P-Value
Overall
Without TXA 3.4% Reference Reference
With TXA 1.6% 0.47 (0.34-0.66) <.001 0.68 (0.46-0.99) .045
With anemia
Without TXA 7.8% Reference Reference
With TXA 5.6% 0.70 (0.42-1.17) .175 1.14 (0.60-2.17) .683
No anemia
Without TXA 2.3% Reference Reference
With TXA 1.1% 0.46 (0.29-0.71) .001 0.52 (0.32-0.84) .008
Hip
Without TXA 4.2% Reference Reference
With TXA 1.7% 0.39 (0.25-0.60) <.001 0.50 (0.31-0.81) .005
Knee
Without TXA 2.6% Reference Reference
With TXA 1.6% 0.59 (0.35-0.98) .042 1.18 (0.63-2.23) .600
TXA, tranexamic acid; PJI, periprosthetic joint infection; OR, odds ratio; CI, confidence interval.
H. Yazdi et al. / The Journal of Arthroplasty 35 (2020) 840e844 843allogeneic blood transfusions and are at higher risk of developing
PJI [13e16]. Thus, strategies to optimize anemic patients preoper-
atively and minimize blood loss during surgery have been imple-
mented to reduce the need for allogeneic blood transfusion [25].
One such strategy has been the administration of TXA during TJA
with proven efficacy to reduce blood loss and the need for alloge-
neic blood transfusion [17e19,26e30]. The current study corrobo-
rates the findings of prior studies by demonstrating an excellent
efficacy for TXA. Patients in the current study who received TXA
had less Hgb drop postoperatively and were less likely to require
blood transfusion and had lower rate of postoperative wound
complications. This group also had shorter length of hospital stay
and lower rate of PJI.
A recent study demonstrated additional benefits to TXA when
administered to patients undergoing TKA [31]. Patients receiving
TXA had less hidden blood loss, a lower ratio of postoperative knee
swelling, less postoperative knee pain, lower levels of inflammatory
biomarkers, better early knee function, and better satisfaction than
those treated with tourniquet alone [32]. Administration of TXA is
also safe with no real concerns that can be gleaned from the liter-
ature. TXA has also been exonerated from causing venous throm-
boembolism (VTE). A recently published meta-analysis concluded
that administration of topical, IV, and oral TXA was not associated
with an increased risk of VTE [33]. We also found no differences
between both groups in terms of DVT, pulmonary embolism, and
90-day readmissions.
Most of the patients who received TXA were also placed on
aspirin for VTE prophylaxis. Heller et al [34] have demonstrated
that TXA can be used along with aspirin safely in arthroplasty pa-
tients without increasing the risk of subsequent VTE. Our results
also showed that this combination did not affect the rate of DVT,
pulmonary embolism, and readmissions. In addition, a study by
Kim et al [35] detected that administration of intra-articular TXA
resulted in fewer wound complications compared to patients who
did not receive TXA. We also observed a similar finding.
The confounding variable that influences blood loss during TKA is
the issue of tourniquet. Alcelik et al [36] in a systemic review
concluded that the total and intraoperative blood loss was less when
a tourniquet was used. On the other hand, Yi et al [37] published a
meta-analysis demonstrating that the use of tourniquet during TKA
resulted in a higher rate of PJI. In our cohort, most of the knee sur-
geries (96.6%) were donewith the use of tourniquet and both groups
were similar in terms of tourniquet use. We are not able to study the
influence of tourniquet on blood loss and examine its potential
confounding effect. The other confounding variable relates to the
type of anesthesia used during TJA. Studies comparing neuraxial
anesthesia with general anesthesia during TJA have reportedconflicting observations. But the overwhelming majority of studies
demonstrate that the use of hypotensive neuraxial anesthesia leads
to a lower blood loss, lower rate of SSI, wound complications, and
fewer overall complications than those receiving general anesthesia
[38e40]. Our results also confirmed previous studies.
Bivariate analysis has shown that in addition to TXA, other vari-
ables such as male gender, BMI, Charlson Comorbidity Index, rheu-
matoid arthritis, renal disease, liver disease, coagulopathy, anemia,
operation time, and length of stay affect the PJI rate after primary TJA
which is supported by the literature [2,3,13,15,21,23,41e44]. After
adjusting for all variables related to outcomes, TXA was an inde-
pendent risk factor protecting against PJI. The protective effect of
TXA was more in hip joints and nonanemic patients.
The unadjusted and adjusted models predicting PJI may be
affected by variations in patients with or without TXA. Patients who
did not receive TXA in the current study tended to be male, older,
sicker, anemic, higher BMI, and less likely to receive aspirin for DVT
prophylaxis or neuraxial anesthesia. These reasons for not receiving
TXAwere due to previous traditional contraindications of TXA in our
hospital. These variables are also predisposing factors for increased
PJI. Based on recent studies on the safety of TXA, the indications for
TXA are increasing even in sicker patients [33,35,45,46]. In an effort
to remove the influence of these variables, we did perform a
regression analysis to identify the influence of TXA administration
alone on the incidence of PJI. The regression analysis revealed that
TXA is associated with reduced PJI after primary TJA.
This study does have several strengths. First, we extracted data
from the clinical charts of all these patients that resulted in
obtaining more accurate data than relying on administrative data.
Second, all patients at our institution are followed closely for the
first 90 days by nurse navigators. Thus, it is unlikely that any com-
plications or readmissions in these patients, even when presented
to an outside facility, weremissed. Third, we attempted to study the
influence of various risk factors on PJI and adjust for these con-
founding variables in the statistical analyses. Finally, weused a strict
definition for PJI removing subjective evaluations to define PJI.
This study also has some limitations. First, it is a retrospective
study with all possible biases that such study design introduces. In
our hospital, TXA has been used since 2012. Initially, it was admin-
istrated in small groups of healthier patients. In 2013-2014, the in-
dications forTXAwereexpandedgraduallyandwehadmorepatients
who received TXA. Recently, almost all TJAs are done with the
administration of TXA. To have more patients with enough follow-
ups and less time-dependent confounding factors, we selected all
primary TJAs from January 1, 2013 to June 31, 2017. This restricted the
number of cases andprobably affected our results in themultivariate
model for anemic patients. Second, this study was not performed
H. Yazdi et al. / The Journal of Arthroplasty 35 (2020) 840e844844usingmatchingcriteria.Weattempted toperformmatchingbasedon
strict criteria, but even in case of one-by-one matching, a high attri-
tion was observed. Third, this study was completed at an urban,
tertiary referral center that does a high volume of primary TJA, and
results may not be generalizable to all centers.
Conclusion
Based on the findings of this study, TXA appears to be associated
with reduced PJI following primary TJA. Although the exact reason
for such finding is unknown, we speculate that the beneficial effect
on TXAmay relate to its efficacy in reducing blood loss and the need
for allogeneic blood transfusion, both of which are known to in-
fluence SSI after all surgical procedures including TJA.
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